|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that MI triggered NLRP3 inflammasome activation leading to conversion of interleukin-1β (IL-1β) and IL-18 into their active mature forms in the heart, which could expand the infarct size and drive cardiac dysfunction.
|
31645662 |
2020 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In contrast, CC genotype of IL-1β and GG genotype of TNF-α have protective effect against myocardial infarction.
|
21380730 |
2011 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, IL-1 and IL-6 gene polymorphisms did not affect MI at younger age (MI<40) or older age (MI>40).
|
21199393 |
2011 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The IL-6C and APOE epsilon4 alleles were independently associated with a mild or moderate increased risk of MI, whilst the allele C of the IL-1beta was not independently linked to MI risk.
|
15336915 |
2004 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The objective of the study is to assess the modulatory effect of IL-1 genotypes on risk mediated by Lp(a) METHODS: We assessed whether IL-1 genotypes modulate the effect of Lp(a) on major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke/transient ischemic attack) and angiographically determined coronary artery disease (CAD).
|
29310992 |
2019 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
IL-1β-511C/T gene polymorphism may be related to the risk of MI complicated with IS.
|
30542472 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac nerve sprouting after MI is associated in part with NF-κB activation in the PVN, and IL-1β is involved in the process.
|
31175933 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cases had higher levels of IL-1Ra at all time-points leading up to first-time MI, and higher levels of IL-1Ra were associated with approximately 1.5-fold increased risk of MI, supporting the rationale to target IL-1 activation in order to reduce cardiovascular risk in PWH.
|
31077280 |
2020 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The IL-1 gene polymorphisms were found to play a role in the development of CAD, especially MI, in patients with CP infection.
|
11527622 |
2001 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data indicate that IL-1β-511TT/CC influence on the risk of myocardial infarction and ischemic stroke at young age through NF-κB, iNOS, MMP-2 and Bax.
|
26823694 |
2015 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy.
|
31652822 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition.
|
30010800 |
2018 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of IL-1β are associated with adverse remodeling, and inhibition of IL-1 signaling after MI results in improved contractile function.
|
28111350 |
2017 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Systemic administration of 2-deoxyglucose after rodent MI normalized the hyperpolarized [1-<sup>13</sup>C]lactate signal in healing myocardial segments at day 3 and also caused dose-dependent improvement in IL (interleukin)-1β expression in infarct tissue without impairing the production of key reparative cytokines.
|
29440071 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, CANTOS trial using an interleukin-1 beta antibody confirmed that inflammatory cytokines contribute to the occurrence of myocardial infarction and cardiac death independent of changes in lipids.
|
30918936 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A similar trend was identified for the expression of NF-κB, IL-1β and MMP-2, which was significantly increased in the MI group compared with that in the sham group (P<0.01), while it was significantly decreased in the MG and PDTC groups compared with that in the MI group (P<0.01).
|
30112065 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, the data indicated that the knockdown of Mincle in microglia within the PVN prevents VAs by attenuating sympathetic hyperactivity and ventricular susceptibility, in part by inhibiting its downstream NLRP3/IL-1β axis following MI.
|
30353660 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, a recent Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial revealed the efficacy of IL-1β inhibition in preventing recurrent cardiovascular events in patients with MI.
|
30930410 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of the pro-inflammatory cytokines interleukin-6 and interleukin-1β were upregulated in hearts of vehicle treated animals compared to mice without MI.
|
29169754 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that antagonism of interleukin (IL)-1β reduces coronary heart disease in patients with a previous myocardial infarction and evidence of systemic inflammation, indicating that pathways required for IL-1β secretion increase cardiovascular risk.
|
29588315 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) showed the successful anti-inflammatory benefit of canakinumab, a monoclonal antibody targeting interleukin-1ß (IL-1ß) toward major cardiovascular events (MACE) in patients with a previous myocardial infarction (MI).
|
31469975 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
All in all, miR-132 inhibits cardiomyocyte apoptosis so as to ameliorate myocardial remodeling in rats with MI through IL-1β downregulation.
|
31621911 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, these data highlight a key role for the IL-1R1/cardiac fibroblast signaling axis in regulating post-MI remodeling and provide support for the continued development of anti-IL-1 therapies for improving cardiac function after MI.
|
31393855 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
With the injection of neutralizing antibodies against IL-1β, control mice and MPGKO mice had comparable cardiac function and expression of inflammatory genes after MI.
|
29800789 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fifteen haplotype-tagging single nucleotide polymorphisms (SNPs) in the IL-1α (IL1A), IL-1β (IL1B), and IL-1 receptor antagonist (IL-1RN) genes were determined in the Health 2000 survey (n = 6771) and European myocardial infarction (MI) survivors (n = 972).
|
20178882 |
2010 |